An observational study in Allergic Rhinitis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by University Hospital, Strasbourg, France · Observational
Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses).
Therefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression.
Tbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
This study's planned enrollment of 30 is below the median of 120 across 143 observational studies indexed under Rhinitis, Allergic.
Browse Rhinitis, Allergic studies →University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult (≥18 years) having follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Self-Assessment Clinical Symptom Score (SCST)
1. Rating Scale Each symptom is rated by the patient according to its intensity: * 0: absent * 1: mild * 2: moderate * 3: severe 2. Calculating the Score * Add the scores for each symptom. * The total SCST score reflects the overall severity of the symptoms: * Low score → mild symptoms * High score → severe symptoms 3. Interpretation * Before treatment: establish a baseline. * After treatment: compare the scores to assess effectiveness. * A decrease in the score indicates clinical improvement.
Time frame: Up to 6 months
Started Jun 2025 (actual). Primary completion is estimated for Feb 2026, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →